JP2002517244A - 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物 - Google Patents

前立腺癌において示差的に調節される遺伝子および遺伝子発現産物

Info

Publication number
JP2002517244A
JP2002517244A JP2000553584A JP2000553584A JP2002517244A JP 2002517244 A JP2002517244 A JP 2002517244A JP 2000553584 A JP2000553584 A JP 2000553584A JP 2000553584 A JP2000553584 A JP 2000553584A JP 2002517244 A JP2002517244 A JP 2002517244A
Authority
JP
Japan
Prior art keywords
polynucleotide
sequence
seq
polypeptide
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000553584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002517244A5 (https=
Inventor
ジョン エイチ． アステル，
エディー ザ サード キャロル，
ウィルソン オー． エンデジ，
ドナ エム． フォード，
ジョン イー． モナハン，
ロバート シェルゲル，
キャスリーン イー． スタインマン，
ジミー ザン，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2002517244A publication Critical patent/JP2002517244A/ja
Publication of JP2002517244A5 publication Critical patent/JP2002517244A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2000553584A 1998-06-11 1999-06-10 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物 Pending JP2002517244A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8887798P 1998-06-11 1998-06-11
US60/088,877 1998-06-11
US09/328,475 US6476207B1 (en) 1998-06-11 1999-06-09 Genes and gene expression products that are differentially regulated in prostate cancer
US09/328,475 1999-06-09
PCT/US1999/013181 WO1999064594A2 (en) 1998-06-11 1999-06-10 Genes and gene expression products that are differentially regulated in prostate cancer

Publications (2)

Publication Number Publication Date
JP2002517244A true JP2002517244A (ja) 2002-06-18
JP2002517244A5 JP2002517244A5 (https=) 2006-07-20

Family

ID=26779140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000553584A Pending JP2002517244A (ja) 1998-06-11 1999-06-10 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物

Country Status (5)

Country Link
US (2) US6476207B1 (https=)
EP (1) EP1086218A2 (https=)
JP (1) JP2002517244A (https=)
ES (1) ES2402095T3 (https=)
WO (1) WO1999064594A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070982A2 (en) * 2000-03-23 2001-09-27 Immusol Incorporated Brca-1 regulators and methods of use
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US6156515A (en) * 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
JP2002543839A (ja) * 1999-05-14 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド ヒト組織に発現する完全長分子
US20020168638A1 (en) * 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2001251013A1 (en) * 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
JP2003528630A (ja) * 2000-03-28 2003-09-30 カイロン コーポレイション ヒト遺伝子および発現産物
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
EP1847620A3 (en) * 2000-10-13 2008-10-22 Cedars-Sinai Medical Center Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1474528A4 (en) * 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
US7037652B2 (en) * 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002055700A2 (en) * 2000-12-07 2002-07-18 Chiron Corp Human genes and gene expression products isolated from human prostate
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
AU2004263140A1 (en) * 2003-08-07 2005-02-17 Novartis Vaccines And Diagnostics, Inc. Trefoil factor 3 (TFF3) as a target for anti-cancer therapy
JP5068543B2 (ja) * 2004-02-16 2012-11-07 プロテオジス アクチェンゲゼルシャフト がんに関する診断マーカー
US7657383B2 (en) * 2004-05-28 2010-02-02 International Business Machines Corporation Method, system, and apparatus for compactly storing a subject genome
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
MXPA00009654A (es) * 1994-08-31 2005-09-08 Univ Johns Hopkins Med Deteccion de secuencias de acidos nucleicos hipermutables en tejidos.
US5767258A (en) * 1995-05-12 1998-06-16 The Johns Hopkins University School Of Medicine Cell cycle regulatory gene
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5594402A (en) * 1995-06-02 1997-01-14 International Power Group, Inc. High voltage isolating transformer module
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5861248A (en) * 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
US6455305B1 (en) * 1996-11-21 2002-09-24 Cedars-Sinai Medical Center Pituitary-tumor-transforming-genes, and related products

Also Published As

Publication number Publication date
WO1999064594A3 (en) 2000-08-17
US20020192699A1 (en) 2002-12-19
US6476207B1 (en) 2002-11-05
WO1999064594A8 (en) 2000-06-02
ES2402095T3 (es) 2013-04-26
EP1086218A2 (en) 2001-03-28
WO1999064594A9 (en) 2000-10-12
WO1999064594A2 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
US7122373B1 (en) Human genes and gene expression products V
JP2002517244A (ja) 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物
JP2003518920A (ja) 新規なヒト遺伝子および遺伝子発現産物
US20020076735A1 (en) Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP2004502406A (ja) ヒト遺伝子およびヒト遺伝子発現産物
JP2002519000A (ja) ヒト遺伝子および遺伝子発現産物ｉｉ
US20070243176A1 (en) Human genes and gene expression products
JP2002500010A (ja) ヒト遺伝子および遺伝子発現産物ｉ
JP2011254830A (ja) 結腸癌に関するポリヌクレオチド
JP2003530816A (ja) ヒト遺伝子および遺伝子発現産物
JP2004533206A (ja) 化学療法のための標的としてのガン関連遺伝子
JP2003528630A (ja) ヒト遺伝子および発現産物
US7883896B2 (en) Marker molecules associated with lung tumors
JP2004526429A (ja) ヒト前立腺から単離したヒト遺伝子および遺伝子発現産物
EP1466988A2 (en) Genes and gene expression products that are differentially regulated in prostate cancer
JP2005046137A (ja) 新規ヒト遺伝子および遺伝子発現産物
AU2904099A (en) Chondrosarcoma associated genes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091126